Last reviewed · How we verify
NCT07041827: CLARITY
Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma
trial testing Cardiovascular assessment in Non Hodgkin Lymphoma in 217 participants. Completed in 1 February 2023.
1 October 2022
Quick facts
| Lead sponsor | The Netherlands Cancer Institute |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 217 |
| Start date | 1 February 2020 |
| Primary completion | 1 October 2022 |
| Estimated completion | 1 February 2023 |
| Sites | 1 location across Netherlands |
Drugs / interventions tested
- Cardiovascular assessment
Conditions studied
- Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →
- DLBCL — all drugs for DLBCL →
- Cardiovascular Diseases — all drugs for Cardiovascular Diseases →
- Cardiomyopathies — all drugs for Cardiomyopathies →
Sponsor
The Netherlands Cancer Institute
Who can join
Adults 18 to 75, any sex, with Non Hodgkin Lymphoma or DLBCL. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Survivors of non-Hodgkin lymphoma and a control group will be screened for (sub)clinical cardiovascular disease, to assess the influence of contemporary treatments on risk and burden of (sub)clinical cardiovascular disease and their influence on survival.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07041827
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cardiovascular assessment
Trials testing the same drug.
- NCT05916287 — FAMILY INHERITANCE, GENE-GENE AND GENE-ENVIRONMENT INTERACTIONS IN THE FIELD OF CARDIOVASCULAR AND RENAL DISEASES. Fifth · NA · recruiting
Other recruiting trials for Non Hodgkin Lymphoma
Currently open trials in the same condition.
- NCT07410494 — Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07016165 — Ciprofloxacin vs Ceftazidime for Empirical Treatment of High-Risk Neutropenic Fever in Children With Hematologic Maligna · Phase 4 · recruiting
- NCT06622226 — A Study of ONO-7018 in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma · Phase 1 · active not recruiting
- NCT06522932 — PET Imaging Study of 64Cu-GRIP B for Patients Receiving CD19-directed CAR-T Therapy · Phase 1 · recruiting
- NCT06116110 — Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU · recruiting
Other The Netherlands Cancer Institute trials
Trials by the same sponsor.
- NCT07436858 — Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER · Phase 1 · not yet recruiting
- NCT07071727 — Short Course of Radiotherapy Prior to Surgery of Soft Tissue Sarcomas · NA · recruiting
- NCT06931769 — TAO-Towards Optimal (Neo)Adjuvant Systemic Therapy of Stage III Triple-negative Breast Cancer · recruiting
- NCT06273800 — Chemosensitivity During Phases of the Menstrual Cycle in Breast Cancer Patients · NA · recruiting
- NCT07310758 — Contrast-enhanced Ultrasound for Sentinel Node Detection · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07041827 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Netherlands Cancer Institute
- Last refreshed: 27 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07041827.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing